VEA
CARM

Virtus ETF Advisers’s Carisma Therapeutics CARM Stock Holding History

Virtus ETF Advisers’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,501
Closed -$40K – 383
2021
Q3 		$40K Sell
2,501
-131
-5% -$6.29K 0.02% 395
2021
Q2 		$243K Buy
+2,632
New +$168K 0.1% 219

Other funds holding CARM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Virtus ETF Advisers's CARM Position: Q4 2021 in Review

Virtus ETF Advisers sold out of Carisma Therapeutics (CARM) in Q4 2021, closing a stake of 2,501 shares — an estimated $40K sold.

Virtus ETF Advisers first reported a position in CARM in Q2 2021 and held it in 2 quarters. The position peaked at $243K in Q2 2021. 93 funds tracked by Wall St. Rank hold CARM as of Q4 2021.

  • Virtus ETF Advisers reported no remaining Carisma Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Virtus ETF Advisers sold 2,501 Carisma Therapeutics shares in Q4 2021, an estimated $40K.
  • Virtus ETF Advisers first reported a position in Carisma Therapeutics in Q2 2021 and held it in 2 quarters.
  • Virtus ETF Advisers's Carisma Therapeutics position peaked at $243K in Q2 2021.
  • 93 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2021.

Based on Virtus ETF Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.